Alan Wake 2 has passed 3 million sales while Remedy revenue has softened ahead of Control Resonant. The milestone shows how Remedy is using long-tail franchise sales to support its next major launch.
Image: IGDB
Alan Wake 2 crosses 3 million as Remedy’s quarter gets tighter
Alan Wake 2 has surpassed 3 million lifetime sales, Remedy Entertainment confirmed in its H1 2026 financial report, according to GamesIndustry.biz, GamingBolt, IGN, Twisted Voxel, and Wccftech. The milestone lands at an awkward but revealing moment for the Finnish studio: Remedy revenue is down year over year, marketing spend is rising, and Control Resonant is being positioned as the company’s next major commercial test ahead of its September 24 launch.
The tension is the story. Alan Wake 2 sales are still moving at what Remedy described as an “expected pace,” according to GamingBolt’s reading of the financial report, and the game’s second-quarter royalties came entirely from consumer sales rather than platform deal accruals, according to GamesIndustry.biz and Twisted Voxel. That is a cleaner signal than a one-time subscription or platform payment. It suggests players are still buying the game directly more than two years after its October 2023 release.
At the same time, GamesIndustry.biz reports that Remedy’s Q2 2026 revenue fell 40% to €10.2 million, while the company posted a €3.9 million operating loss. For the first half of 2026, revenue was €23.3 million, down 23.1%. Twisted Voxel also reports that EBITDA declined from €6.8 million to €0.5 million, and that Remedy moved from an operating profit to an operating loss in the first half. GamesIndustry.biz’s summary lists the H1 operating comparison as a €0.8 million profit in 2023, while Twisted Voxel frames the same comparison against 2025; the common point across the coverage is that H1 2026 profitability weakened.
That makes the Alan Wake 2 3 million milestone less of a victory lap and more of a case study in Remedy’s operating model: expensive, distinctive single-player games that may need time, expansions, catalogue reinforcement, and franchise cross-pollination before their economics fully mature.
The long tail is now doing real work
Alan Wake 2 did not behave like a front-loaded blockbuster. GamingBolt notes that it reached 1.3 million sales by February 2024, making it Remedy’s fastest-selling title, then passed 2 million in February 2025, at which point it had recouped development and marketing costs. The new figure, over 3 million, means the game has added at least another million sales after reaching profitability.
That matters because the nature of the revenue has changed. GamesIndustry.biz reports that royalties from Alan Wake 2 and Alan Wake Remastered in the quarter came solely from consumer sales, with no platform deal accruals. GamingBolt makes the same point in more direct terms, saying that after recouping costs, further sales are effectively royalties, especially without platform deal accruals in the period.
For a strategy-minded read, that is the cleanest part of Remedy’s report. The launch window proved the game could command attention. The post-launch window is proving whether the audience keeps expanding after the marketing spike fades. Alan Wake 2 has had help from two paid expansions, Night Springs and The Lake House, both cited by GamingBolt, and The Lake House also teases the events of Control Resonant. That is not incidental connective tissue. It is catalogue design.
Remedy’s games increasingly function like pieces of a shared shelf, where a new release can push old games back into the conversation and old games can make the new release easier to sell. The reported increase in Control sales during Q2, supported by Control Resonant marketing according to GamesIndustry.biz, is the same system working in the opposite direction. Alan Wake 2 keeps earning after launch. Control gets a lift before its sequel. The studio’s back catalogue becomes a buffer while the next big swing is still burning cash.
Softer revenue is partly timing, partly the cost of the next push
The revenue decline is not being presented by Remedy as a collapse in demand for its core franchises. GamesIndustry.biz reports that Remedy attributed its Q2 and H1 declines to the prior launch of FBC: Firebreak during the comparison period and increased marketing for Control Resonant. Wccftech similarly reports that Q2 2025 benefited from FBC: Firebreak and initial subscription-service accruals, making the year-over-year comparison tougher.
The game sales and royalty line shows the size of that timing effect. GamesIndustry.biz reports that revenue from game sales and royalties fell to €3.8 million from €9.5 million in the same period last year, when FBC: Firebreak and initial subscription service accruals contributed. Development fees from Control Resonant and the Max Payne 1 & 2 remake were €6.4 million in the quarter, compared with €7.4 million in the previous period. Twisted Voxel reports H1 development fees of €14.5 million, down from €18.1 million.
IGN adds another piece of context: FBC: Firebreak, described as Remedy’s multiplayer experiment, received its final update in March after low sales. That detail sharpens the contrast between Remedy’s recent bets. Firebreak appears, from the sourced reporting, to have provided a short-term comparison boost through launch and subscription-related revenue, but it is not the growth pillar Remedy is currently emphasizing. Alan Wake 2, by contrast, has become a long-tail royalty contributor. Control Resonant is being prepared as the next premium franchise release.
The practical read is that Remedy is spending into a launch while comparing against a period inflated by a different kind of release. That does not erase the operating loss, but it changes how to judge it. A studio investing in marketing before a September release should look worse in June than it hopes to look after launch. The risk is whether Control Resonant converts attention into sales quickly enough to validate that spending.
Control Resonant is being asked to do several jobs at once
Control Resonant is the center of Remedy’s near-term plan. GamesIndustry.biz reports that CEO Jean-Charles Gaudechon said pre-orders opened with “healthy momentum,” and that the game ranked among the top three pre-ordered PlayStation games in the US, Germany, and Brazil. The same report says Control Resonant has more than 1.5 million wishlists, a figure also reported by IGN, GamingBolt, Twisted Voxel, Wccftech, and the KAMI post on X summarizing Remedy’s financial report.
Gaudechon’s comments, as quoted by GamesIndustry.biz, are carefully confident rather than triumphant. “Our data indicates the game is tracking well against comparable titles in its launch window,” he said. “In a competitive autumn window, we believe the distinctiveness and quality of the game will make it stand out.” IGN quotes him saying Remedy is positioning Control Resonant as “a must-have day-one purchase” while building Control into a lasting franchise, and notes his view that the release window has become slightly less crowded since the original reveal.
That is the key strategic pivot. Remedy is not treating Control Resonant as a quiet sequel for existing fans. It is leaning on wishlists, pre-orders, platform coverage, catalogue momentum, and franchise identity to create a more immediate launch result than Alan Wake 2 delivered. Wccftech reports that Remedy has highlighted a shift toward faster, melee-led combat as a debated but ultimately well-received change from the original game. If that lands, Resonant could broaden Control’s audience. If it alienates players who prized the first game’s rhythm, it could create launch friction at the exact moment Remedy needs conversion.
The company’s own language acknowledges the challenge. Gaudechon said, according to GamesIndustry.biz, that early signals and commercial metrics give Remedy confidence in Resonant’s potential, but that the focus remains on bringing an outstanding game to market and letting results speak. For all the wishlist numbers, this is still a premium launch in a competitive autumn window, and wishlists are intent, not revenue.
The Remedy Connected Universe is becoming a business tool
The Alan Wake and Control connection has long been a creative hook, but the current financial update shows how it also supports Remedy’s commercial planning. GamingBolt notes that Alan Wake 2’s The Lake House expansion teased the events of Control Resonant. GamesIndustry.biz reports that Control sales increased in Q2 with support from ongoing marketing for Control Resonant. IGN quotes Gaudechon saying Remedy has two established owned franchises, Control and Alan Wake, linked through the Remedy Connected Universe, and that growing and expanding those franchises will be a key part of the company’s future.
That strategy suits Remedy’s strengths, but it comes with a discipline test. Shared universes can raise average engagement when players feel each release deepens the next one. They can also become homework if the path into a new game feels too tangled. Remedy appears to be threading that line by using Alan Wake 2 expansions and Control marketing as connective signals rather than requiring every player to enter at the same point.
The strongest evidence is the catalogue movement. Alan Wake 2 continues to sell at an expected pace after profitability. Alan Wake Remastered still generates royalty revenue, according to GamesIndustry.biz and Twisted Voxel. Control saw a sales increase as its sequel campaign ramped up. For a studio that makes authored, high-production games, the ideal scenario is not one giant launch spike followed by silence. It is a series of releases and expansions that keep the catalogue legible to new players.
That is also why self-publishing matters. IGN quotes Gaudechon saying Remedy will self-publish upcoming games in which it owns the IP. If Remedy owns the franchise and controls publishing, the long-tail upside of catalogue sales, expansions, pricing strategy, and cross-promotion should matter more to its financial model. The tradeoff is exposure. Self-publishing can mean more control over upside, but it also puts more launch execution risk on Remedy itself.
Platforms, timing, and the questions players can actually act on
Alan Wake 2 is available on PS5, Xbox Series X/S, and PC, according to GamingBolt. Control Resonant is scheduled for September 24, 2026. IGN reports the game is launching for PC, PlayStation 5, and Xbox Series X/S, while GamesIndustry.biz’s page also tags Mac alongside PC, PS5, and Xbox Series X/S. The sourced reports do not provide a detailed explanation for that platform discrepancy, so the safest reader guidance is to treat PC, PS5, and Xbox Series X/S as the consistently reported launch platforms and to wait for Remedy or storefront listings for firm Mac availability.
IGN reports Gaudechon saying Control Resonant will be available across all major platforms from day one and is “priced attractively for an AAA title,” but the provided source material does not include a specific price. That means buyers still lack some practical information, including final pricing by region, technical performance targets, PC requirements, and any edition or upgrade structure. Those details will matter if Remedy is pushing day-one conversion rather than relying on a slower Alan Wake 2-style climb.
For players catching up now, the financial report indirectly strengthens the case for Remedy’s older catalogue. Alan Wake 2 has recouped its costs and continues to sell. Control is seeing renewed interest ahead of Resonant. Alan Wake Remastered still contributes royalties. None of that says every player needs to buy immediately, but it does indicate these games are still commercially active rather than abandoned releases.
For Remedy, the next checkpoint is sharper. Alan Wake 2 sales passing 3 million confirms that the studio can build value after launch. Control Resonant now has to prove Remedy can turn that accumulated franchise value into a stronger day-one outcome while revenue is under pressure and marketing costs are already on the books. The long tail is working. September will show whether the front end of the strategy is strong enough to match it.